Pro Medicus Ltd
ASX:PME

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
ASX:PME
Watchlist
Price: 248.65 AUD -0.63% Market Closed
Market Cap: 26B AUD
Have any thoughts about
Pro Medicus Ltd?
Write Note

Net Margin
Pro Medicus Ltd

49.8%
Current
47%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
49.8%
=
Net Income
82.8m
/
Revenue
166.3m

Net Margin Across Competitors

Country AU
Market Cap 26B AUD
Net Margin
50%
Country US
Market Cap 36.3B USD
Net Margin
25%
Country US
Market Cap 31.3B USD
Net Margin
10%
Country US
Market Cap 10.8B USD
Net Margin
34%
Country US
Market Cap 6.3B USD
Net Margin
-6%
Country JP
Market Cap 927.2B JPY
Net Margin
16%
Country US
Market Cap 5.6B USD
Net Margin
4%
Country SE
Market Cap 52.8B SEK
Net Margin
25%
Country US
Market Cap 2.4B EUR
Net Margin
-4%
Country CN
Market Cap 17B CNY
Net Margin
11%
Country US
Market Cap 2.1B USD
Net Margin
-2%
No Stocks Found

Pro Medicus Ltd
Glance View

Market Cap
26B AUD
Industry
Health Care
Economic Moat
Wide

Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments. The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.

PME Intrinsic Value
30.32 AUD
Overvaluation 88%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
49.8%
=
Net Income
82.8m
/
Revenue
166.3m
What is the Net Margin of Pro Medicus Ltd?

Based on Pro Medicus Ltd's most recent financial statements, the company has Net Margin of 49.8%.